| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
Form 4: Duncan Charles Cliff, Director
Bought 750 shares ($2.85K) · Bought 3,447 shares ($13.2K) · Bought 5,803 shares ($22.1K) |
| 29 Oct 2026 | 10-Q |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
WASHINGTON – October 28, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026. |
| 27 Oct 2026 | SCHEDULE 13G |
| 09 Oct 2026 | SCHEDULE 13G/A |
| 19 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
WASHINGTON – August 5, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026. |
| 08 Jun 2026 |
Form 4: McGuire Daniel Patrick, SVP, GC and Secretary
Received 80,000 shares as a grant or award |
| 08 Jun 2026 |
Form 4: Chrousos Phaedra, Director
Received 41,600 shares as a grant or award |
| 08 Jun 2026 |
Form 4: Duncan Charles Cliff, Director
Received 41,600 shares as a grant or award |
| 08 Jun 2026 |
Form 4: Dugan Richard W, Director
Received 41,600 shares as a grant or award |
| 08 Jun 2026 |
Form 4: Ward Anne Sempowski, Director
Received 41,600 shares as a grant or award |
| 08 Jun 2026 |
Form 4: Honore Tage, Director
Received 41,600 shares as a grant or award |
| 08 Jun 2026 |
Form 4: Mitchell Stephen Ray, Director
Received 41,600 shares as a grant or award |
| 08 Jun 2026 |
Form 3: McGuire Daniel Patrick, SVP, GC and Secretary
Holds 1,732 shares of Common Stock |
| 05 Jun 2026 | S-8 |
Loading...